Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) Short Interest Update

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest totaling 76,503 shares, an increase of 44.6% from the November 30th total of 52,895 shares. Based on an average daily volume of 57,093 shares, the short-interest ratio is currently 1.3 days. Currently, 0.5% of the company’s stock are short sold. Currently, 0.5% of the company’s stock are short sold. Based on an average daily volume of 57,093 shares, the short-interest ratio is currently 1.3 days.

Wall Street Analysts Forecast Growth

BWAY has been the topic of a number of recent research reports. Northland Securities boosted their price objective on Brainsway from $19.00 to $23.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 12th. HC Wainwright raised their target price on Brainsway from $18.00 to $24.00 and gave the company a “buy” rating in a report on Monday, December 8th. Wall Street Zen upgraded Brainsway from a “hold” rating to a “buy” rating in a report on Saturday, December 13th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Brainsway in a research note on Monday, December 22nd. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $23.50.

Brainsway Stock Performance

NASDAQ:BWAY opened at $19.37 on Monday. The stock has a market cap of $379.26 million, a price-to-earnings ratio of 64.57 and a beta of 1.22. Brainsway has a one year low of $7.84 and a one year high of $19.80. The business’s 50-day simple moving average is $16.61 and its 200 day simple moving average is $14.75.

Brainsway (NASDAQ:BWAY) last posted its quarterly earnings data on Tuesday, November 11th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.03). The business had revenue of $13.51 million for the quarter, compared to analysts’ expectations of $13.04 million. Brainsway had a return on equity of 9.46% and a net margin of 12.73%. On average, equities research analysts predict that Brainsway will post 0.08 EPS for the current year.

Institutional Investors Weigh In On Brainsway

Several hedge funds and other institutional investors have recently modified their holdings of the stock. UBS Group AG raised its stake in shares of Brainsway by 2,028.6% in the 3rd quarter. UBS Group AG now owns 63,878 shares of the company’s stock valued at $963,000 after purchasing an additional 60,877 shares in the last quarter. Two Sigma Investments LP increased its holdings in Brainsway by 25.2% in the third quarter. Two Sigma Investments LP now owns 102,902 shares of the company’s stock valued at $1,551,000 after buying an additional 20,706 shares during the last quarter. Y.D. More Investments Ltd acquired a new stake in Brainsway during the third quarter valued at approximately $263,000. Millennium Management LLC lifted its holdings in Brainsway by 69.6% during the 3rd quarter. Millennium Management LLC now owns 39,841 shares of the company’s stock worth $600,000 after buying an additional 16,354 shares during the last quarter. Finally, Trexquant Investment LP acquired a new position in shares of Brainsway in the 1st quarter worth approximately $129,000. Institutional investors own 30.11% of the company’s stock.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.